XGXin Gao

Xin Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xin Gao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Yinyi Chen

    Clinical Laboratory, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China

    3 shared publications
  • Changshun Yang

    Clinical Laboratory The First People's Hospital of Huaihua Huaihua Hunan China

    2 shared publications
  • Hong‐Lei Liu

    The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of China

    2 shared publications
  • Jian-Ping Cai

    The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    2 shared publications
  • Jin Li

    The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of China

    2 shared publications
  • Jinlian Yang

    Clinical Laboratory The First People's Hospital of Huaihua Huaihua Hunan China

    2 shared publications

Latest Publications

  • Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction

    by Xin Gao, Xue-Jian Zhou

    Cellular senescence (CS) exerts dual roles in tumorigenesis, yet its pan-cancer molecular characteristics and clinical value remain unclear, hindering its translation to oncology and personalized therapy. To address the lack of specific and universal tools for senescence assessment and immunotherapy response prediction, this study systematically analyzed 1259 CS-related genes from the CellAge database across 31 cancer types by integrating multi-omics data, including bulk RNA-seq, single-cell/spatial transcriptomics, and CRISPR screening. We developed a rank-based algorithm SenScoreR (publicly available at https://gxhub.shinyapps.io/SenScoreR/) for senescence quantification, validated with 10 independent datasets, and constructed a machine learning-based predictive model CS.Sig for immunotherapy response. Results showed that tumors had significantly lower Rank-based Senescence Score (RSS) than normal tissues across 31 cancers (average diagnostic AUC = 0.895), with low RSS linked to poor survival; high RSS correlated with reduced genomic instability, enriched CD8⁺ T/NK cell/macrophage infiltration, upregulated PD-L1 expression, and elevated immune cytolytic activity. CS.Sig demonstrated robust performance in predicting ICI response (AUC = 0.716 across 10 cohorts), outperforming 13 existing signatures, while CRISPR screening identified 17 senescence-related targets (e.g., CEP55, PPP1CC) whose knockout enhanced anti-tumor immunity. Our findings clarify CS’s role in maintaining tumor genomic stability and shaping immune microenvironments, and the developed SenScoreR, CS.Sig, and identified targets bridge basic CS research with clinical oncology, providing a translational resource and hypothesis basis for future experimental and clinical validation.

  • Open Access

    An Aging Clock Based on Immune Repertoire Features: COVID ‐19 Accelerates Aging

    by Xin Gao, Si‐Jia Li, Jin Li, Zi‐Hui Wang, Lv‐Tao Zeng, Ya‐Qing Ma, Ya‐Min Dang, Ying‐Min Zhang, Hong‐Lei Liu, Li‐Qun Zhang, et al.

    Aging induces immunosenescence, a progressive decline in immune function underpinning age‐related pathogen vulnerability, yet T/B cell receptor (TCR/BCR) repertoire remodeling during aging remains incompletely characterized, especially in non‐European populations. Additionally, SARS‐CoV‐2 may perturb immune homeostasis and accelerate aging, but its impact on immune repertoire aging is unclear. Here, we analyzed leukocyte DNA from 195 healthy Chinese individuals (25–93 years) and 94 post‐COVID‐19 cases via CDR3 high‐throughput sequencing. Aging correlated with shorter CDR3 sequences, reduced VDJ gene/V‐J combination diversity, declining TCR/BCR clonotype counts (179.7/507 per 3 years), expanded hyperexpanded TCR/large BCR clones, and reduced diversity (critical turning point ~60 years). These changes were intensified post‐COVID‐19, with altered amino acid usage, diminished diversity, and expanded SARS‐CoV‐2/ Mycobacterium tuberculosis ‐related clones. We developed a LightGBM‐based immune repertoire aging clock, validating accelerated biological aging (increased cAgeDiff) and reduced intrinsic capacity in post‐COVID‐19 individuals. Our findings reveal age‐dependent immune repertoire remodeling exacerbated by COVID‐19, deepening understanding of immunosenescence and post‐viral dysfunction, with potential clinical applications for age‐related immune decline and post‐COVID‐19 syndromes.

  • Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms

    by Yuan Liu, Shao-Hui Zou, Xin Gao

    Background Bladder cancer is a prevalent malignancy. CDC20, a pivotal cell cycle regulator gene, plays a significant role in tumour cell proliferation, but its role in bladder cancer remains unclear. Objective This study aimed to analyse CDC20 expression in bladder cancer and explore its roles in tumour progression, treatment response, patient prognosis, and cellular proliferation mechanisms. Methods We systematically analysed CDC20 expression in bladder cancer using bioinformatics. Our study investigated the impact of CDC20 on chemotherapy and radiotherapy sensitivity, patient prognosis, and changes in CDC20 methylation levels. We also explored the role and potential underlying mechanisms of CDC20 in bladder cancer cell growth. We used lentiviral transfection to downregulate CDC20 expression in 5637 and T24 cells, followed by CCK-8, colony formation, scratch, invasion, apoptosis, and cell cycle analyses. Results CDC20 is highly expressed in bladder cancer and is significantly correlated with poor prognosis. Moreover, CDC20 demonstrated high diagnostic potential for bladder cancer (AUC > 0.9). The tumour methylation levels of CDC20 in tumour tissues markedly decreased compared with those in normal tissues, and lower methylation levels were associated with a worse prognosis. Elevated CDC20 expression is linked to increased mutation burden. Our findings suggested a potential association between high CDC20 expression and resistance to chemotherapy and radiotherapy, as CDC20 expression may impact immune cell infiltration levels. Mechanistic analysis revealed the influence of CDC20 on bladder cancer cell proliferation through cell cycle-related pathways. According to the cell experiments, CDC20 downregulation significantly impedes bladder cancer cell proliferation and invasion, leading to G1 phase arrest. Conclusion Aberrantly high CDC20 expression promotes tumour progression in bladder cancer, resulting in a poor prognosis, and may also constitute a promising therapeutic target.


  • Open Access

    Exploring the potential role of oxidative stress‐related genes in colorectal cancer recurrence and establishing a recurrence assessment system based on single‐cell and bulk RNA‐seq analysis

    by Xin Gao, Jin Li, Qing‐Yu Wang, Zi‐Hui Wang, Si‐Jia Li, Lv‐Tao Zeng, Hong‐Lei Liu, Jian‐Ping Cai

  • Open Access

    Genome‐wide screening of SARS‐CoV‐2 infection‐related genes based on the blood leukocytes sequencing data set of patients with COVID‐19

    by Xin Gao, Yuan Liu, Shaohui Zou, Pengqin Liu, Jing Zhao, Changshun Yang, Mingxing Liang, Jinlian Yang

    Coronavirus disease 2019 (COVID‐19) is a global epidemic disease caused by a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), causing serious adverse effects on human health. In this study, we obtained a blood leukocytes sequencing data set of COVID‐19 patients from the GEO database and obtained differentially expressed genes (DEGs). We further analyzed these DEGs by protein–protein interaction analysis and Gene Ontology enrichment analysis and identified the DEGs closely related to SARS‐CoV‐2 infection. Then, we constructed a six‐gene model (comprising IFIT3, OASL, USP18, XAF1, IFI27, and EPSTI1) by logistic regression analysis and calculated the area under the ROC curve (AUC) for the diagnosis of COVID‐19. The AUC values of the training group, testing group, and entire group were 0.930, 0.914, and 0.921, respectively. The six genes were highly expressed in patients with COVID‐19 and positively correlated with the expression of SARS‐CoV‐2 invasion‐related genes (ACE2, TMPRSS2, CTSB, and CTSL). The risk score calculated by this model was also positively correlated with the expression of TMPRSS2, CTSB, and CTSL, indicating that the six genes were closely related to SARS‐CoV‐2 infection. In conclusion, we comprehensively analyzed the functions of DEGs in the blood leukocytes of patients with COVID‐19 and constructed a six‐gene model that may contribute to the development of new diagnostic and therapeutic ideas for COVID‐19. Moreover, these six genes may be therapeutic targets for COVID‐19.


  • Identification of a four immune‐related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma

    by Xin Gao, Jinlian Yang, Yinyi Chen

    Renal clear cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, which has strong immunogenicity. A comprehensive study of the role of immune‐related genes (IRGs) in ccRCC is of great significance in finding ccRCC treatment targets and improving patient prognosis. In this study, we comprehensively analyzed the expression of IRGs in ccRCC based on The Cancer Genome Atlas datasets. The mechanism of differentially expressed IRGs in ccRCC was analyzed by bioinformatics. In addition, Cox regression analysis was used to screen prognostic related IRGs from differentially expressed IRGs. We also identified a four IRGs signature consisting of four IRGs (CXCL2, SEMA3G, PDGFD, and UCN) through lasso regression and multivariate Cox regression analysis. Further analysis results showed that the four IRGs signature could effectively predict the prognosis of patients with ccRCC, and its predictive power is independent of other clinical factors. In addition, the correlation analysis of immune cell infiltration showed that this four IRGs signature could effectively reflect the level of immune cell infiltration of ccRCC. We also found that the expression of immune checkpoint genes CTLA‐4, LAG3, and PD‐1 in the high‐risk group was higher than that in the low‐risk group. Our research revealed the role of IRGs in ccRCC, and developed a four IRGs signature that could be used to evaluate the prognosis of patients with ccRCC, which will help to develop personalized treatment strategies for patients with ccRCC and improve their prognosis. In addition, these four IRGs may be effective therapeutic targets for ccRCC.


  • Open Access

    Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells

    by Xin Gao, Xiaohong Wen, Haowei He, Linlin Zheng, Yibo Yang, Jinlian Yang, Haifang Liu, Xiguo Zhou, Changshun Yang, Yinyi Chen, et al.

    Bladder cancer is a tumour of the urinary system with high mortality, and there is also a great lack of therapeutic targets in the clinic. Cell division cycle associated 8 (CDCA8), an important component of the vertebrate chromosomal passenger complex, is highly expressed in various tumours and promotes tumour development. However, the role of CDCA8 in bladder cancer is not fully understood. This study aimed to reveal the function of CDCA8 in bladder cancer by determining the relationship between CDCA8 expression and proliferation, metastasis and apoptosis of bladder cancer cells. Firstly, we studied the mRNA expression of CDCA8 through the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases and analysed the correlation between CDCA8 expression and prognosis of patients with bladder cancer. We also verified CDCA8 expression in bladder cancer tissues by immunohistochemistry. In addition, CDCA8 expression was inhibited in bladder cancer T24 and 5637 cells, and the effects of CDCA8 on the proliferation, migration and invasion of bladder cancer cell lines were investigated using cell counting kit-8, colony formation, cell cycle, apoptosis, wound healing and Transwell invasion assays. Results showed that CDCA8 was highly expressed in bladder cancer compared with normal tissues, and the high CDCA8 expression was significantly correlated with the poor prognosis of patients. Inhibiting CDCA8 expression inhibited the proliferation, migration and invasion of T24 and 5637 cells and induced the apoptosis of bladder cancer cells. CDCA8 was involved in the regulation of the growth cycle of bladder cancer cells. Bioinformatics-based mechanism analysis revealed that high CDCA8 expression may affect the cell cycle and P53 signalling pathways. In conclusion, our results suggest that CDCA8 is highly expressed in bladder cancer and can promote tumour development. Hence, CDCA8 may serve as an effective therapeutic target for treatment of bladder cancer.


  • Development of a novel six‐long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma

    by Xin Gao, Shufang Zhang, Yinyi Chen, Xiaohong Wen, Mei Chen, Shunlan Wang, Yingai Zhang

    Bladder urothelial carcinoma is a malignant tumor with a high incidence in the uropoietic system. Considerable studies have shown that long noncoding RNA (lncRNA) plays an important role in the development and progression of bladder urothelial carcinoma. In this study, the lncRNA expression and clinical data of 377 bladder urothelial carcinoma patients were obtained from The Cancer Genome Atlas database and differentially expressed lncRNAs in cancer and normal groups were evaluated. Univariate COX and multivariate COX regression analyses of prognosis were performed on differentially expressed lncRNAs in the training data sets, six prognosis‐related lncRNAs (LINC02195, LINC01484, LINC01468, SMC2‐AS1, AC011298.1, and PTPRD‐AS1) were assessed, and a six‐lncRNA signature was constructed. The predictive capability of this six‐lncRNA signature was validated in the testing data sets and entire data sets. The prognostic ability of the six‐lncRNA signature was independent of other clinical elements after multivariate COX regression and stratified analyses of with other clinical elements. We performed functional enrichment analysis with the six prognosis‐related lncRNAs. Results of functional enrichment revealed that these prognosis‐related lncRNAs might promote the development and metastasis of bladder urothelial carcinoma. In summary, the six‐lncRNA signature that we developed could effectively predict the prognosis of bladder urothelial carcinoma patients. This six‐lncRNA signature might be a novel independent prognostic marker of bladder urothelial carcinoma. Moreover, it also provides novel insights into the mechanism of bladder urothelial carcinoma.


  • Open Access

    ILKAP Binding to and Dephosphorylating HIF-1α is Essential for Apoptosis Induced by Severe Hypoxia

    by Tielong Liu, Yonggang Liu, Jiashi Cao, Xin Gao, Jing Wang, Guanghui Chen, Yang Wang, Ge Liu, Guangjian Bai, Yiwei Hu, et al.

    Background/Aims: Integrin-linked kinase-associated phosphatase (ILKAP), a serine/threonine phosphatase that belongs to the protein phosphatase 2C family, has a role in cell survival and apoptosis. Hypoxia-inducible factor 1α (HIF-1α) is the key transcription factor in the response to oxygen deficiency in mammals. Direct phosphorylation and dephosphorylation of HIF-1α affect its function. The present study investigated the role of ILKAP on HIF-1α dephosphorylation and cell behavior. Methods: HIF-1α was induced by hypoxia. Physical binding between ILKAP and HIF-1α was demonstrated by a co-immunoprecipitation assay. HIF-1α transcriptional activity was investigated using a hypoxia-response element-containing luciferase reporter plasmid. Cell viability was evaluated by a trypan blue dye exclusion assay. ILKAP function was explored by a gain and loss assay with an overexpression plasmid and shRNA infection. Results: ILKAP physically interacted with HIF-1α and induced its dephosphorylation. Both the HIF-1α-p53 interaction and apoptosis relied on ILKAP. Conclusion: The results indicated that the ILKAP directly binds and dephosphorylates HIF-1α and responsible for severe hypoxia-induced cell apoptosis.